Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MATTHEW HAROLD KATZ and EUGENE JON KOAY.
MATTHEW HAROLD KATZ
Connection Strength
5.066
EUGENE JON KOAY
  1. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med. 2024 Jun; 13(12):e7434.
    View in: PubMed
    Score: 0.244
  2. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg. 2023 07 01; 278(1):22-30.
    View in: PubMed
    Score: 0.226
  3. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.215
  4. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):163-172.
    View in: PubMed
    Score: 0.213
  5. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
    View in: PubMed
    Score: 0.207
  6. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer. 2022 Jan 03; 22(1):14.
    View in: PubMed
    Score: 0.207
  7. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.196
  8. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers (Basel). 2020 Dec 05; 12(12).
    View in: PubMed
    Score: 0.192
  9. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.188
  10. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.185
  11. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Ann Surg Oncol. 2020 Oct; 27(10):3939-3947.
    View in: PubMed
    Score: 0.183
  12. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.176
  13. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
    View in: PubMed
    Score: 0.163
  14. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.157
  15. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.155
  16. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17(1):505.
    View in: PubMed
    Score: 0.152
  17. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.147
  18. Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget. 2016 Dec 27; 7(52):85776-85784.
    View in: PubMed
    Score: 0.146
  19. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.144
  20. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.140
  21. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.126
  22. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.120
  23. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol. 2024 Aug 05; JCO2400081.
    View in: PubMed
    Score: 0.062
  24. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist. 2024 Jul 16.
    View in: PubMed
    Score: 0.062
  25. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Ann Surg. 2024 Mar 20.
    View in: PubMed
    Score: 0.060
  26. Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024 Sep 01; 120(1):111-119.
    View in: PubMed
    Score: 0.060
  27. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 12; 24(12):1387-1398.
    View in: PubMed
    Score: 0.059
  28. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy. Cancers (Basel). 2023 Jun 18; 15(12).
    View in: PubMed
    Score: 0.057
  29. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Cancers (Basel). 2023 May 04; 15(9).
    View in: PubMed
    Score: 0.057
  30. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol. 2023 04 01; 47(4):421-430.
    View in: PubMed
    Score: 0.056
  31. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490.
    View in: PubMed
    Score: 0.055
  32. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022 12 15; 132(24).
    View in: PubMed
    Score: 0.055
  33. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Pancreatology. 2021 Oct; 21(7):1378-1385.
    View in: PubMed
    Score: 0.050
  34. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Adv Radiat Oncol. 2021 Nov-Dec; 6(6):100763.
    View in: PubMed
    Score: 0.050
  35. CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT. Abdom Radiol (NY). 2021 06; 46(6):2620-2627.
    View in: PubMed
    Score: 0.048
  36. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.048
  37. Circulating levels of hydroxylated bradykinin function as an indicator of tissue HIF-1a expression. Sci Bull (Beijing). 2020 Sep 30; 65(18):1570-1579.
    View in: PubMed
    Score: 0.046
  38. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2020 Jan-Feb; 9(1):24-30.
    View in: PubMed
    Score: 0.045
  39. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019 May; 4(5):223-225.
    View in: PubMed
    Score: 0.043
  40. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics. 2018; 8(21):5986-5994.
    View in: PubMed
    Score: 0.042
  41. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.041
  42. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4.
    View in: PubMed
    Score: 0.041
  43. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):403-415.
    View in: PubMed
    Score: 0.037
  44. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng. 2017; 1.
    View in: PubMed
    Score: 0.037
  45. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.036
  46. Transforming Growth Factor-? Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clin Cancer Res. 2016 Oct 01; 22(19):4934-4946.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.